AndzonBio2 has signed agreements with the Alborada Drug Discovery Institute (ADDI) at the University of Cambridge and Cambridge Enterprise to advance a new class of therapeutics targeting neuroinflammation, a central driver of multiple neurodegenerative and neurological conditions, such as Parkinson’s, Alzheimer’s, Amyotropic Lateral Sclerosis, and other CNS disorders.
Neurological and neurodegenerative disorders affect over 3 billion people, and effective disease-modifying treatments remain limited. Increasing scientific evidence indicates that neuroinflammation is a key biological driver of disease progression, making it an important emerging therapeutic target.
Under the agreement, the parties will combine AndzonBio2’s expertise in early drug development and translational strategy with Cambridge’s neuroscience capabilities and ADDI’s drug discovery platform. They aim to progress a novel, first-in-class therapeutic program to modulate key pathways involved in neuroinflammatory processes.
Loic Lhuillier, CEO of AndzonBio2, said, “We are thrilled to enter this collaboration with the ADDI at Cambridge. Neuroinflammation is at the core of many severe brain diseases, and new therapeutic solutions are urgently needed. By combining our complementary strengths, we have a unique opportunity to accelerate the development of a highly innovative therapeutic approach with the potential to change the treatment landscape for patients.”
Cambridge Enterprise grants AndzonBio2 an option to license the resulting intellectual property from the collaboration and enhance the program through preclinical and clinical development. The partnership is structured to integrate academic discovery with industry-grade drug development, facilitating progress toward candidate nomination and future clinical testing.
Professor John Skidmore, chief scientific officer of the Alborada Drug Discovery Institute at the University of Cambridge, said, “We are delighted to collaborate with AndzonBio2 on this promising project. This partnership exemplifies our commitment to translating cutting-edge neuroscience into impactful therapies. AndzonBio2 brings a focused expertise in neuroinflammation and drug development that will be instrumental in driving this promising programme forward.”
